When was Cerecor founded?

Cerecor was founded in 2011 and raised its 1st funding round 1 year after it was founded.

Where is Cerecor located?

Cerecor is headquartered in Baltimore, United States. It is registered at 1500 Liberty Ridge Drive Suite 321 Wayne, PA 19087.

How many employees does Cerecor have?

As of Mar 31, 2026, the latest employee count at Cerecor is 48.

Is Cerecor a funded company?

Cerecor is a funded company, having raised a total of $45.2M across 6 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Apr 04, 2012.

When was the latest funding round of Cerecor?

Cerecor's latest funding was a $***** Post IPO round on Apr 28, 2017, with participation from 1 investor. Its primary sector is Immunology. In United States, the Immunology sector has seen $2.94B in funding in 2026 to date.

Where does Cerecor rank among its competitors?

Cerecor ranks 57th amongst 394 active competitors, of which 132 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was Alto Neuroscience, which secured $120M in Mar, 2026.

Who are the top competitors of Cerecor?

Cerecor's top competitors include Septerna, Evommune and Alto Neuroscience. Among them, Alto Neuroscience secured the most recent funding round in March, 2026.

Cerecor - 2026 Company Profile, Funding & Competitors

Company Details

Developer of therapeutics for Immunological disorders and neurological disorders. The product pipeline includes CERC-002 for pediatric crohn's disease, CERC-007 for inflammatory arthritis, and multiple myeloma, CERC-802, CERC-803 for congenital disorders.

Website: cerecor.com
Registered Address: 1500 Liberty Ridge Drive Suite 321 Wayne, PA 19087

Key Metrics

Founded Year

2011

Location

Baltimore, United States

Stage

Public

Total Funding

$45.2M in 6 rounds

Latest Funding Round

Post IPO, Apr 28, 2017, $*****

Investors

New Enterprise Associates & 5 more

Ranked

57^th among 394 active competitors

Employee Count

48 as on Mar 31, 2026

Investment & Acquisitions

Aevi Genomic Medicine & 2 more

Similar Companies

Septerna & 486 more

Exit Details

Public

View Cerecor's full profile

Cerecor is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Avalo Therapeutics, Inc. CIN: 45-0705648 , United States, Active	Jan 30, 2011	$0 - $1M (As on Dec 31, 2025)	20 (As on Dec 31, 2022)	-
Avalo Therapeutics, Inc. CIN: 598472 , United States, Active	Apr 11, 2019	-	-	-

Cerecor got listed on Nov 20, 2015.

Click here to take a look at Cerecor's IPO in detail

Cerecor has raised a total funding of $45.2M over 6 rounds. Its first funding round was on Apr 04, 2012. Its latest funding round was a Post IPO round on Apr 28, 2017 for $*****. 1 investor participated in its latest round. Cerecor has 6 institutional investors.

Here is the list of recent funding rounds of Cerecor:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 28, 2017	4839161	Post IPO	1989075	1137749	8573562	6197713
Sep 16, 2016	8358396	Post IPO	9636188	7544210	6329022	Hercules Capital
Apr 11, 2016	6647408	Grant (prize money)	8958326	8849160	6426225	NIH

Access funding benchmarks and valuations. Sign up today!

View details of Cerecor's funding rounds and investors

Cerecor's employee count trend

Cerecor has 48 employees as of Mar 26. Here is Cerecor's employee count trend over the years:

Uncover Cerecor's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Cerecor include Septerna, Evommune and Alto Neuroscience. Here is the list of Top 10 competitors of Cerecor, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Septerna 2020, San Bruno (United States), Public	Developer of GPCR drug discovery platform for multiple diseases	$250M	RA Capital Management, Third Rock Ventures ... & 14 others	71/100
2nd	Evommune 2020, Sacramento (United States), Public	Developer of therapeutic options for chronic inflammatory disorders	$276M	Pivotal bioVenture Partners, Sectoral & 18 others	69/100
3rd	Alto Neuroscience 2019, San Francisco (United States), Public	AI-driven drug discovery platform for neurological diseases based on patients biomarkers	$145M	Commodore Capital, Alkeon Capital Management ... & 36 others	68/100
4th	Upstream Bio 2021, Waltham (United States), Public	Developer of therapeutics for allergic and inflammatory diseases	$400M	Venrock, Orbimed & 11 others	67/100
5th	Odyssey 2018, Cambridge (United States), Public	Developer of immunotherapeutics for immunological and cancer diseases	$717M	General Catalyst, Orbimed & 29 others	66/100
6th	Ventyx Biosciences 2018, Encinitas (United States), Acquired	Developer of therapeutics to treat autoimmune diseases	$165M	VenBio, Logos Capital & 13 others	66/100
7th	Beckley Psytech 2019, Oxford (United Kingdom), Series B	Developer of rapid-acting psychedelic medicines for mental health disorders	$153M	ATAI, Bain Capital & 26 others	64/100
8th	CalciMedica 2006, San Diego (United States), Public	Developer of CRAC channel inhibitor drugs for inflammatory diseases	$76.7M	Biogen, SR One & 11 others	64/100
9th	Enveda 2019, Boulder (United States), Series D	AI-based platform to decipher the chemistry of nature and develop new medicines	$517M	Premji Invest, Kinnevik & 29 others	63/100
10th	Vanda Pharmaceuticals 2003, Washington, DC (United States), Public	Developer of pharmaceutical products for treating CNS disorders	$33.5M	MedImmune Ventures, EDBI & 4 others	62/100
57th	Cerecor 2011, Baltimore (United States), Public	Developer of therapeutics for Immunological disorders and neurological disorders	$45.2M	Hercules Capital, Armistice Capital & 4 others	49/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Cerecor's competitors? Click here to see the top ones

Cerecor has acquired 3 companies including Aevi Genomic Medicine, Karbinal ER and Trxpharma. Cerecor has not made any investments as of now.

Here is the list of its acquisitions:

Date of Investment/Acquisition	Type	Company Name	Founded Year	Location
Dec 05, 2019	Acquisition	Aevi Genomic Medicine	2001	Wayne (United States)
Feb 12, 2018	Acquisition	Karbinal ER	2011	Chesterfield (United States)
Nov 17, 2017	Acquisition	Trxpharma		United States